Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
6 papers
Recent·Most cited
A. K. Najumudeen, S. K. Fey, L. M. Millet…·O. J. Sansom
This study shows that wild-type KRAS suppresses tumour growth and metastasis in KRAS mutant colorectal cancer while enhancing resistance to MEK inhibition.
S. K. Fey, A. K. Najumudeen, C. A. Ford…·O. J. Sansom
This study shows that loss of wild-type Kras enhances oncogenic Kras signaling and promotes pancreatic ductal adenocarcinoma, while also increasing sensitivity to MEK1/2 inhibitors.
J. Vande Voorde, A. K. Najumudeen, R. T. Steven…·O. J. Sansom
This study uses metabolomics to stratify colorectal cancer tissues and identifies adenosylhomocysteinase as a potential therapeutic target.
J. Lilja, J. Kaivola, J. R. W. Conway…·J. Ivaska
This study identifies SHANK3 as a RAS interactor that limits oncogenic KRAS signaling, and shows that disrupting its interaction with KRAS induces cell death in KRAS-mutant cancers.
A. K. Holt, A. K. Najumudeen, A. J. Hoskin…·E. E. Vincent
This study shows aspirin reprograms colorectal cancer cell metabolism and increases sensitivity to glutaminase inhibition, suggesting potential for improved metabolic therapies in CRC.
E. Gil Vazquez, N. Nasreddin, G. N. Valbuena…·S. J. Leedham
The paper examines stem cell population dynamics in colorectal tumors, showing that CBC-RSC admixture correlates with mutations and microenvironmental changes, and is linked to chemoresistance.